UNLIMITED TURBO SHORT - ELI LILLY & CO | Real-time Bid/Ask 05:12:36 2024-06-27 EDT | ||
| 3.96 EUR / 4.11 EUR | -9.53% |
|
| Current month | -61.78% | ||
| 1 month | -63.97% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 4.07 | -8.74% |
| 24-06-26 | 4.46 | +4.21% |
| 24-06-25 | 4.28 | -14.40% |
| 24-06-24 | 5 | -13.04% |
| 24-06-21 | 5.75 | -4.96% |
Delayed Quote Börse Stuttgart
Last update June 27, 2024 at 03:35 am
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PC68PV |
| ISIN | DE000PC68PV0 |
| Date issued | 2024-03-25 |
| Strike | 941.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 15.3 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 20.73 € |
|---|---|
| Lowest since issue | 3.78 € |
| Spread | 0.15 € |
| Spread % | 3.50% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
901.3
USD
Average target price
860.5
USD
Spread / Average Target
-4.52%
- Stock Market
- Certificates
- Certificat
